GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » Valuation Rank

Rafael Holdings (Rafael Holdings) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Rafael Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Rafael Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rafael Holdings (Rafael Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » Valuation Rank
Comparable Companies
LODE OMH FLJ FTHM BRST NYC MDJH LRHC HWTR GYRO CSGP CBRE XMAD:CLNX BEKE TSE:8830 HKSE:01972 OSTO:AKEL D SGX:9CI HKSE:01997 MIL:INW
Traded in Other Exchanges
N/A
Address
520 Broad Street, Newark, NJ, USA, 07102
Website
https://www.rafaelholdings.com
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.
Executives
I9 Plus, Llc 10 percent owner 153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas director
Mary Margaret Huizinga officer: Chief Devel. & Medical Officer C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin officer: Chief Legal Officer C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio officer: Chief Financial Officer 2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger director 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik officer: CHIEF EXECUTIVE OFFICER C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling officer: Chief Commercial Officer C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss director C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg director C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky officer: Chief Financial Officer 90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash director, officer: President C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102